Evaluation in 18 patients with polycythemia vera showed hematocrit control below 45%, accompanied by a "dramatic decrease in ...

CURE spoke with Dr. Marina Kremyanskaya about the treatment landscape for patients with polycythemia vera.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients ...

Marissa Johanna Maria Traets Bridging Pathophysiology and Therapeutic Targets in Sickle Cell Disease dr. M.A.E. Rab ...

Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...

DEAR DR. ROACH: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his ...

Dear Dr. Roach: My husband was diagnosed with secondary polycythemia in 2011. His hematocrit test (HCT) was 57%. He was referred to a hematologist. The hematologist would order a phlebotomy when his ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Iron Overload Syndrome Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...

Petersburg native Frenchie Burks opened Burks Phlebotomy On The Go, LLC, a brick-and-mortar location of her nearly five-year-old mobile phlebotomy business. Burks, a certified phlebotomist and ...

Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) ...